Natural killer cell activity and cytokine production as prognostic factors in adult acute leukemia

Leukemia

Volumn 10, Issue 3, 1996, Pages 478-482

  Tajima, F ^a   Kawatani, T ^a   Endo, A ^a   Kawasaki, H ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Acute leukemia; Interferon gamma; Interleukin 1 ; Interleukin 2; Natural killer cell activity

Indexed keywords

ACLARUBICIN; CYCLOPHOSPHAMIDE; CYTOKINE; DAUNORUBICIN; DOXORUBICIN; ENOCITABINE; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 2; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; VINCRISTINE; VINDESINE;

ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; ASSAY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; MALE; MONONUCLEAR CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; PROGNOSIS; RELAPSE;

EID: 0029887832     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Karre K, Klein GO, Kiessling R, Klein G, Roder, JC. Low natural in vivo resistance to syngeneic leukaemias in natural killer-deficient mice. Nature 1980; 284: 624-626.
2. Herberman RB, Ortaldo JR. Natural killer cells: their role in defenses against disease. Science 1981; 214: 24-30.
3. Beran M, Hansson M, Kiessling R. Human natural killer cells can inhibit clonogenic growth of fresh leukemic cells. Blood 1983; 61: 596-599.
4. Trentin L, Pizzolo G, Feruglio C, Zambello R, Masciarelli M, Bulian P, Agostini C, Vinante F, Zanotti R, Semenzato G. Functional analysis of cytotoxic cells in patients with acute nonlymphoblastic leukemia in complete remission. Cancer 1989; 64: 667-672.
5. Mageed AA, Findley HW Jr, Franco C, Singhapakdi S, Alvarado C, Chan WC, Ragab AH. Natural killer cells in children with acute leukemia: the effect of interleukin-2. Cancer 1987; 60: 2913-2918.
6. Lotzova E, Savary CA, Herberman RB. Induction of NK cell activity against fresh human leukemia in culture with interleukin 2. J Immunol 1987; 138. 2718-2727.
7. Yabuhara A, Kawai H. A recycling defect as a characteristic of natural killer cells in childhood acute lymphoblastic leukemia. Pediatr Res 1990; 28: 572-578.
8. Sorskaar D, Forre O, Albrechtsen D, Stavem P. Natural cytotoxicity in adult acute leukemia. Int Arch Allergy Immunol 1988; 86: 190-195.
9. Tratkiewicz JA, Szer J. Loss of natural killer activity as an indicator of relapse in acute leukaemia. Clin Exp Immunol 1990; 80. 241-246
10. Eliopoulos GD, Coulocheri SA, Eliopoulos AG, Katrinakis G, Karkavitsas N, Kryiakou D, Valopoulos G, Foudoulakis A. Mechanisms accounting for the impaired natural-killer cell activity in refractory anaemia with excess of blasts. Eur J Haematol 1992; 48: 237-243.
11. Price G, Brenner MK, Prentice HG, Hoffbrand AV, Newland AC. Cytotoxic effects of tumour necrosis factor and gamma-interferon on acute myeloid leukemia blasts. Br J Cancer 1987; 55: 287-290.
12. Klingemann H-G, Phillips GL. Immunotherapy after bone marrow transplantation. Bone Marrow Transplant 1991; 8: 73-81.
13. Kurzrock R, Talpaz M, Kantarjian H, Walters R, Saks S, Trujillo JM, Gutterman JU. Therapy of chronic myelogenous leukemia with recombinant interferon-γ. Blood 1987; 70: 943-947.
14. Ciolli V, Gabriele L, Sestili P, Varano F, Proietti E, Gresser I, Testa U, Montesoro E, Bulgarini D, Mariani G, Peschle C, Belardelli F. Combined interleukin 1/interleukin 2 therapy of mice injected with highly metastatic friend leukemia cells: host antitumor mechanisms and marked effects on established metastases. J Exp Med 1991; 173: 313-322.
15. Benyunes MC, Massumoto C, York A, Higuchi CM, Buckner CD, Thompson JA, Petersen FB, Fefer A. Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 1993; 12: 159-163.
16. Klingemann HG, Eaves CJ, Barnett MJ, Eaves AC, Hogge DE, Nantel SH, Reece E, Shepherd JD, Sutherland HJ, Phillips GL. Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration. Bone Marrow Transplant 1994; 14: 389-396
17. Hamon MD, Prenice HG, Gottlieb DJ, Macdonald ID, Cunningham JM, Smith OP, Gilmore M, Gandhi L, Collis C. Immunotherapy with interleukin 2 after ABMT in AML. Bone Marrow Transplant 1993; 11: 399-401.
18. 51Cr release as a measure of lymphocyte-mediated cytolysis in vitro. Cell Immunol 1973; 9: 474-476.
19. Hauch M, Gazzola MV, Small T, Bordignon C, Barnett L, Cunningham I, Castro-Malaspinia H, O'Reilly RJ, Keever CA. Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood 1990; 75: 2250-2262.
20. + natural killer cells after bone marrow transplantation. Blood 1992; 79: 3239-3244.
21. Sosman JA, Sondel PM. The graft-vs-leukemia effect: implications for post-marrow transplant antileukemia treatment. Am J Pediatr Hematol Oncol 1993; 15: 185-195.
22. Dickinson AM, Proctor SJ, Jacobs E, Reid MM, Walker W, Craft AW, Kernahan J. Natural killer cell activity in childhood acute lymphoblastic leukaemia in remission. Br J Haematol 1985; 59: 45-53.
23. Jermy A, Lilleyman JS, Jennings R, Rees RC. Spontaneous natural killer cell activity in childhood acute lymphoblastic leukaemia. Eur J Cancer 1987; 23. 1365-1370.
24. Pizzolo G, Trentin L, Vinante F, Agostini C, Zambello R, Masciarelli M, Feruglio C, Dazzi F, Todeschini G, Chilosi M, Veneri D, Zanotti R, Benedetti F, Perona G, Semenzato G. Natural killer cell function and lymphoid subpopulations in acute non-lymphoblastic leukaemia in complete remission. Br J Cancer 1988; 58: 368-372.
25. Parrado A, Casares S, Rodriguez-Fernandez J-M. Natural killer cytotoxicity and lymphocyte subpopulations in patients with acute leukemia. Leuk Res 1994; 18: 191-197.
26. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990; 76: 2421-2438.
27. Ellis TM, McKenzie RS, Simms PE, Helfrich BA, Fisher RI. Induction of human lymphokine-activated killer cells by IFN-α and IFN-γ. J Immunol 1989; 143: 4282-4286.
28. McClave PB, Arthur D, Miller WJ, Lasky L, Kersey J. Autologous transplantation for CML using marrow treated ex vivo with recombinant human interferon gamma. Bone Marrow Transplant 1990; 6: 115-120.
29. Clarkson B, Gaynor J, Little C, Berman E, Kempin S, Andreeff M, Gulati S, Cunningham I, Gee T. Importance of long-term follow-up in evaluating treatment regimens for adults with acute lymphoblastic leukemia. Haematol Bluttransfus 1990; 33: 397-408.
30. Ohno R, Kobayashi T, Tanimoto M, Hiraoka A, Imai K, Asou N, Tomonaga M, Tsubaki K, Takahashi I, Kodera Y, Yoshida M, Murakami H, Naoe T, Shimoyama M, Tsukada T, Takeo T, Teshima H, Onozawa Y, Fujimoto K, Kuriyama K, Horiuchi A, Kimura I, Minami S, Miura Y, Kageyama S, Tahara T, Masaoka T, Shirakawa S, Saito H. Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. Cancer 1993; 71: 3888-3895.